Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294877 | 1.00 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL1933560 | 1.00 | CA1 (0.62) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL8930327 | 0.92 | CA1 (0.57) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL18653600 | 0.85 | CA1 (0.60) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL1566002 | 0.85 | CA1 (0.60) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL31208336 | 0.85 | CA1 (0.51) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL13093849 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL1975300 | 0.83 | CA1 (0.46) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL1975297 | 0.83 | CA1 (0.46) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL5153374 | 0.83 | CA1 (0.58) | CA1CA2CA7CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425657-A | Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116171154-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-02-10 | — | — | US | disclosed |
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | LILLY CO ELI (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3223820-B1 | 3-METHYL-2-IMINO-HEXAHYDRO-1H-PYRANO[3,4-D]PYRIMIDIN-4-ONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3497105-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018031334-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031334-A1 | AMINOTHIAZINES AND THEIR USE AS BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-15 | — | — | WO | disclosed |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-8198269-B2 | Fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332943-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-6512003-B2 | Depolymerization activity and polymerization inhibition of tubulin; antiproliferative agents | PARKER HUGHES INSTITUTE | 2003-01-28 | — | — | US | disclosed |
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | PARKER HUGHES INSTITUTE (US) | 2002-10-17 | — | — | US | disclosed |
| US-6335364-B1 | TUBULIN POLYMERIZATION INHIBITORS; ANTIPROLIFERATIVE AND ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2002-01-01 | — | — | US | disclosed |
| EP-1091978-A2 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000514-A9 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INST (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000000514-A2 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355138-A1 | AMINOTHIAZINIES AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | CA1 1624/4885CA2 2406/4885CA7 3682/4885 |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | CA1 866/4885CA2 2251/4885CA7 3297/4885 |
| US-20220041621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CA1 4878/4885CA2 2696/4885CA7 4692/4885 |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | CA1 591/4885CA2 1748/4885CA7 3740/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | CA1 2289/4885CA2 921/4885CA7 159/4885 |
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | TUBB6, TUBAL3, TUBB1 | CA1 3104/4885CA2 3849/4885CA7 3952/4885 |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | CA1 160/4885CA2 2164/4885CA7 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.